Tag: ANP

Antisense Therapeutics ASX ANP Duchenne Muscular Dystrophy drug Phase 2 trial ATL1102

Antisense Therapeutics reports ‘strong initial efficacy’ for Duchenne Muscular Dystrophy drug in Phase 2 trial

Biopharmaceutical company Antisense Therapeutics (ASX: ANP) emerged from a trading halt to announce that its immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD) had met the require...
Duchenne Muscular Dystrophy DMD Antisense Therapeutics ASX ANP inflammation

Antisense Therapeutics set to widen its scope of treatment options

Following recently reported positive clinical trial results relating to its research into Duchenne Muscular Dystrophy, biopharmaceutical drug development company Antisense Therapeutics (ASX: ANP) has ...
Antisense Therapeutics ASX ANP ATL1102 DMD Phase IIb trial Duchenne Muscular Dystrophy

Clinical trial confirms Antisense Therapeutics drug can inhibit progression of Duchenne muscular dystrophy

Data from a phase 2 clinical trial by Antisense Therapeutics (ASX: ANP) on the immunomodulatory therapy ATL1102 for Duchenne muscular dystrophy has confirmed the drug can have positive effects on prog...
Antisense Therapeutics ASX ANP Phase 2 clinical trial Duchenne Muscular Dystrophy DMD

Antisense reports positive early results from clinical trial of new drug to treat patients with Duchenne muscular dystrophy

A preliminary review of a phase two clinical trial involving an immunomodulatory therapy drug developed by Antisense Therapeutics (ASX: ANP) has shown a positive effect for patients with non-amubulant...
Antisense Therapeutics ATL1102 Duchenne Muscular Dystrophy trial

Antisense Therapeutics anticipates trial results for ATL1102 drug on Duchenne Muscular Dystrophy by year-end

Antisense Therapeutics (ASX: ANP) has now completed enrolment for its phase two clinical trial using its immunomodulatory therapy ATL1102 drug on Duchenne Muscular Dystrophy (DMD), with results expect...
Antisense Therapeutics ASX ANP multiple sclerosis study

Antisense Therapeutics reports positive effects in multiple sclerosis study

Antisense Therapeutics (ASX: ANP) has reported that a post hoc analysis of brain lesion data from the Phase II study of the ATL1102 in patients with multiple sclerosis (MS) has shown that ATL1102 sig...